#SFHS2615720VFrance Sets Prices for Selected Pharmaceutical Products
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France sets official prices for a list of pharmaceutical products, including Cimzia and several ustekinumab products sold under brands such as Otulfi, Pyzchiva, Steqeyma and Uzpruvo. The notice lists the product codes, presentations, pre-tax manufacturer prices, retail prices including tax, and effective dates in July 2026. The change mainly affects pharmaceutical companies, pharmacies, wholesalers, health insurers and healthcare purchasers that use these products. Businesses should update pricing systems, reimbursement references and procurement planning before the relevant effective dates.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets official prices for listed pharmaceutical products including Cimzia and ustekinumab products
- Lists both pre-tax manufacturer prices and retail prices including tax
- Applies new prices from specified dates in July 2026
Obligations
What this law requires
Apply the official PFHT price of €508.68 and PPTTC price of €580.33 for CIMZIA 200 mg products listed under CIP codes 3400939732008, 3400930098936, and 3400930076286 from 15 July 2026.
Apply the official PFHT price of €969.04 and PPTTC price of €1,093.82 for OTULFI 45 mg and 90 mg products listed under CIP codes 3400930304143 and 3400930304167 from 22 July 2026.
Apply the official PFHT price of €969.04 and PPTTC price of €1,093.82 for PYZCHIVA ustekinumab 45 mg and 90 mg presentations listed under CIP codes 3400930293416, 3400930315453, 3400930293423, and 3400930315460 from 22 July 2026.
Apply the official PFHT price of €969.04 and PPTTC price of €1,093.82 for STEQEYMA ustekinumab 45 mg and 90 mg presentations listed in the notice from 22 July 2026.